Recent progress in Rett syndrome and MECP2 dysfunction: Assessment of potential treatment options

Future Neurology

Volumn 8, Issue 1, 2013, Pages 21-28

  Chapleau, Christopher A ^a   Lane, Jane ^a   Larimore, Jennifer ^b   Li, Wei ^a   Pozzo Miller, Lucas ^a   Percy, Alan K ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b AGNES SCOTT COLLEGE   (United States)

Author keywords

clinical trials; MeCP2; neurodevelopmental disorders; Rett syndrome

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; AMINOGLYCOSIDE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; BROMOCRIPTINE; CARNITINE; DOPAMINE RECEPTOR; FOLIC ACID; GENTAMICIN; GLUTAMIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; LAMOTRIGINE; LM 22A 4; MACROGOL 3350; MAGNESIUM HYDROXIDE; METHYL CPG BINDING PROTEIN 2; NALTREXONE; NOOTROPIC AGENT; PROTON PUMP INHIBITOR; RECOMBINANT SOMATOMEDIN C; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ALLELE; AUTISM; BDNF GENE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CELL DENSITY; CELL FUNCTION; CELL MOTILITY; CELL SHAPE; CELL SURVIVAL; CHROMOSOME XQ; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE DEVELOPMENT; COMMUNICATION SKILL; CONSTIPATION; DENDRITIC CELL; DENDRITIC SPINE; DIET SUPPLEMENTATION; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DNA METHYLATION; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; GENE; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GLIA; HUMAN; INTELLECTUAL IMPAIRMENT; LIVER DYSFUNCTION; LUNG FIBROSIS; MECP2 GENE; MOTOR DEVELOPMENT; MOTOR PERFORMANCE; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; NUTRITIONAL REQUIREMENT; ONSET AGE; PHYSICAL DEVELOPMENT; POST TETANIC POTENTIATION; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITY OF LIFE; REFERENCE VALUE; RETT SYNDROME; REVIEW; SEIZURE; SIGNAL TRANSDUCTION; SOCIAL EVOLUTION; SYMPTOMATOLOGY; SYNAPTIC TRANSMISSION; TRANSCRIPTION REGULATION; TREATMENT PLANNING; VASOSPASM; X LINKED MENTAL RETARDATION;

EID: 84871191102     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.12.79     Document Type: Review

References (59)

1. Rett A. On a unusual brain atrophy syndrome in hyperammonemia in childhood. Wien. Med. Wochenschr. 116, 723-726 (1966).
2. Hagberg B, Aicardi J, Dias K, Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Ann. Neurol. 14, 471-479 (1983).
3. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23, 185-188 (1999).
4. Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann. Neurol. 68, 944-950 (2010).
5. Percy AK, Neul JL, Glaze DG, et al. Rett syndrome diagnostic criteria: lessons from the Natural History Study. Ann. Neurol. 68, 951-955 (2010).
6. Percy AK. Rett syndrome. Current status and new vistas. Neurol. Clin. 20, 1125-1141 (2002).
7. Kirby RS, Lane JB, Childers J, et al. Longevity in Rett syndrome: analysis of the North American Database. J. Pediatr. 156, 135-138, e131(2010).
8. Tarquinio DC, Motil KJ, Hou W, et al. Growth failure and outcome in Rett syndrome: specific growth references Neurology 79, 1653-1661 (2012)
9. Armstrong D, Dunn JK, Antalffy B, Trivedi R. Selective dendritic alterations in the cortex of Rett syndrome. J. Neuropathol. Exp. Neurol. 54, 195-201 (1995).
10. Belichenko PV, Oldfors A, Hagberg B, Dahlstrom A. Rett syndrome: 3-D confocal microscopy of cortical pyramidal dendrites and afferents. Neuroreport 5, 1509-1513 (1994).
11. Chapleau CA, Calfa GD, Lane MC, et al. Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-Associated MECP2 mutations. Neurobiol. Dis. 35, 219-233 (2009).
12. Percy AK. Rett syndrome: exploring the autism link. Arch. Neurol. 68, 985-989 (2011).
13. Chapleau C, Lane J, Pozzo-Miller L, Percy AK. Evaluation of current pharmacological treatment options in the management of rett syndrome: from the present to future therapeutic alternatives. Curr. Clin. Pharmacology (2012) (In press).
14. Motil KJ, Caeg E, Barrish JO, et al. Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome. J. Pediatr. Gastroenterol. Nutr. 55(3), 292-298 (2012).
15. Glaze DG, Percy AK, Skinner S, et al. Epilepsy and the natural history of Rett syndrome. Neurology 74, 909-912 (2010).
16. Pan JW, Lane JB, Hetherington H, Percy AK. Rett syndrome: 1H spectroscopic imaging at phosphorylation regulates nervous system development and function. Neuron 72, 72-85 (2011).
17. Goffin D, Allen M, Zhang L, et al. Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. Nat. Neurosci. 15(2), 274-283 (2011).
18. Cassel S, Carouge D, Gensburger C, et al. Fluoxetine and cocaine induce the epigenetic factors MeCP2 and MBD1 in adult rat brain. Mol. Pharmacol. 70, 487-492 (2006).
19. Amir RE, Van den Veyver IB, Schultz R, et al. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann. Neurol. 47, 670-679 (2000).
20. Trappe R, Laccone F, Cobilanschi J, et al. MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. Am. J. Hum. Genet. 68, 1093-1101 (2001).
21. Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315, 1143-1147 (2007).
22. Robinson L, Guy J, McKay L, et al. Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome. Brain 135(Pt 9), 2699-2710 (2012).
23. LaSalle JM, Goldstine J, Balmer D, Greco CM. Quantitative localization of heterogeneous methyl-CpG-binding protein 2 (MeCP2) expression phenotypes in normal and Rett syndrome brain by laser scanning cytometry. Hum. Mol. Genet. 10, 1729-1740 (2001).
24. Ballas N, Lioy DT, Grunseich C, Mandel G. Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nat. Neurosci. 12, 311-317 (2009).
25. Maezawa I, Jin LW. Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate. J. Neurosci. 30, 5346-5356 (2010).
26. Maezawa I, Swanberg S, Harvey D, LaSalle JM, Jin LW. Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions. J. Neurosci. 29, 5051-5061 (2009).
27. Okabe Y, Takahashi T, Mitsumasu C, Kosai K, Tanaka E, Matsuishi T. Alterations of gene expression and glutamate clearance in astrocytes derived from an MeCP2-null mouse model of Rett syndrome. PLoS ONE 7, e35354 (2012).
28. Weng SM, McLeod F, Bailey ME, Cobb SR. Synaptic plasticity deficits in an experimental model of rett syndrome: long-term potentiation saturation and its pharmacological reversal. Neuroscience 180, 314-321 (2011).
29. Schaevitz LR, Moriuchi JM, Nag N, Mellot TJ, Berger-Sweeney J. Cognitive and social functions and growth factors in a mouse model of Rett syndrome. Physiol. Behav. 100, 255-263 (2010).
30. D'Ercole AJ, Ye P, Calikoglu AS, Gutierrez-Ospina G. The role of the insulin-like growth factors in the central nervous system. Mol. Neurobiol. 13, 227-255 (1996).
31. D'Ercole AJ, Ye P, O'Kusky Jr. Mutant mouse models of insulin-like growth factor actions in the central nervous system. Neuropeptides 36, 209-220 (2002).
32. Tropea D, Giacometti E, Wilson NR, et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc. Natl Acad. Sci. USA 106, 2029-2034 (2009).
33. Landi S, Putignano E, Boggio EM, Giustetto M, Pizzorusso T, Ratto GM. The short-time structural plasticity of dendritic spines is altered in a model of Rett syndrome. Sci. Rep. 1, 45 (2011).
34. Marchetto MC, Carromeu C, Acab A, et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143, 527-539 (2010).
35. Rowe SM, Clancy JP. Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development. Bio. Drugs 23, 165-174 (2009).
36. Zingman LV, Park S, Olson TM, Alekseev AE, Terzic A. Aminoglycoside- induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy. Clin. Pharmacol. Ther. 81, 99-103 (2007).
37. Brendel C, Klahold E, Gartner J, Huppke P. Suppression of nonsense mutations in Rett syndrome by aminoglycoside antibiotics. Pediatr. Res. 65, 520-523 (2009).
38. Brendel C, Belakhov V, Werner H, et al. Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model. J. Mol. Med. (Berl.). 89, 389-398 (2011).
39. Popescu AC, Sidorova E, Zhang G, Eubanks JH. Aminoglycoside-mediated partial suppression of MECP2 nonsense mutations responsible for Rett syndrome in vitro. J. Neurosci. Res. 88, 2316-2324 (2010).
40. Chen WG, Chang Q, Lin Y, et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 302, 885-889 (2003).
41. Martinowich K, Hattori D, Wu H, et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 302, 890-893 (2003).
42. Deng V, Matagne V, Banine F, et al. FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. Hum. Mol. Genet. 16, 640-650 (2007).
43. Abuhatzira L, Makedonski K, Kaufman Y, Razin A, Shemer R. MeCP2 deficiency in the brain decreases BDNF levels by REST/ CoREST-mediated repression and increases TRKB production. Epigenetics 2, 214-222 (2007).
44. Chang Q, Khare G, Dani V, Nelson S, Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 49, 341-348 (2006).
45. Wang H, Chan SA, Ogier M, et al. Dysregulation of brain-derived neurotrophic factor expression and neurosecretory function in Mecp2 null mice. J. Neurosci. 26, 10911-10915 (2006).
46. Larimore JL, Chapleau CA, Kudo S, Theibert A, Percy AK, Pozzo-Miller L. Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-Associated MECP2 mutations. Neurobiol. Dis. 34, 199-211 (2009).
47. Lioy DT, Wu WW, Bissonnette JM. Autonomic dysfunction with mutations in the gene that encodes methyl-CpG-binding protein 2: insights into Rett syndrome. Auton. Neurosci. 161, 55-62 (2011).
48. Ogier M, Wang H, Hong E, Wang Q, Greenberg ME, Katz DM. Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. J. Neurosci. 27, 10912-10917 (2007).
49. Kline DD, Ogier M, Kunze DL, Katz DM. Exogenous brain-derived neurotrophic factor rescues synaptic dysfunction in Mecp2-null mice. J. Neurosci. 30, 5303-5310 (2010).
50. Schmid DA, Yang T, Ogier M, et al. A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of rett syndrome. J. Neurosci. 32, 1803-1810 (2012).
51. Johnson RA, Lam M, Punzo AM, et al. 7,8-dihydroxyflavone (7,8-DHF) exhibits therapeutic efficacy in a mouse model of Rett syndrome. J. Appl. Physiol. 112(5), 704-710 (2012).
52. Ylisaukko-Oja T, Rehnstrom K, Vanhala R, et al. MECP2 mutation analysis in patients with mental retardation. Am. J. Med. Genet. A. 132A(2), 121-124 (2005).
53. Augenstein K, Lane JB, Horton A, Schanen C, Percy AK. Variable phenotypic expression of a MECP2 mutation in a family. J. Neurodev. Disord. 1, 313 (2009).
54. Samaco RC, Nagarajan RP, Braunschweig D, LaSalle JM. Multiple pathways regulate MeCP2 expression in normal brain development and exhibit defects in autism-spectrum disorders. Hum. Mol. Genet. 13, 629-639 (2004).
55. Shibayama A, Cook EH Jr, Feng J, et al. MECP2 structural and 3'-UTR variants in schizophrenia, autism and other psychiatric diseases: a possible association with autism. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 128B, 50-53 (2004).
56. Ramocki MB, Peters SU, Tavyev YJ, et al. Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome. Ann. Neurol. 66, 771-782 (2009).
57. Cohen D, Lazar G, Couvert P, et al. MECP2 mutation in a boy with language disorder and schizophrenia. Am. J. Psychiatry 159, 148-149 (2002).
58. Online Mendelian Inheritance in Man® #312750. www.ncbi.nlm.nih.gov/ omim
59. Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection). www.clinicaltrials.gov/ct2/show/NCT012533 17?term=NCT01253317&rank=1